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Abstract
Stroke patients are at high risk of developing pneumonia, which is major cause of post-
stroke mortality. Proton pump inhibitors and H2 receptor antagonists are anti-ulcer drugs,
which may predispose to the development of pneumonia by suppression of the gastric acid
with bactericidal activity. Unlike proton pump inhibitors and H2 receptor antagonists, muco-
protective agents have gastroprotective effects with no or less anti-acid property. We aimed
to investigate effects of the acid-suppressive medications (proton pump inhibitors and H2
receptor antagonists) and mucoprotective agents on risk for post-stroke pneumonia using
the National Health Insurance Service-National Sample Cohort in Korea. This retrospective
cohort study included 8,319 patients with acute ischemic stroke. Use of proton pump inhibi-
tors, H2 receptor antagonists, and mucoprotective agents (rebamipide, teprenone, irsogla-
dine, ecabet, polaprezinc, sofalcone, sucralfate, and misoprostol) after stroke were
determined based on the prescription records, which were treated as time-dependent vari-
ables. Primary outcome was the development of post-stroke pneumonia. During the mean
follow-up period of 3.95 years after stroke, 2,035 (24.5%) patients had pneumonia. In the
multivariate time-dependent Cox regression analyses (adjusted hazard ratio [95% confi-
dence interval]), there was significantly increased risk for pneumonia with use of proton
pump inhibitors (1.56 [1.24–1.96]) and H2 receptor antagonists (1.40 [1.25–1.58]). In con-
trast to the proton pump inhibitors and H2 receptor antagonists, use of mucoprotective
agents did not significantly increase the risk for pneumonia (0.89 [0.78–1.01]). In conclusion,
the treatment with proton pump inhibitors and H2 receptor antagonists was associated with
increased risk for pneumonia in stroke patients. Clinicians should use caution in prescribing
the acid-suppressive medications for the stroke patients at great risk for pneumonia.
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Introduction
Stroke is the leading cause of death and long-term disability worldwide [1]. Stroke victims fre-
quently have aspiration events and coexisting comorbidity such as old age, diabetes mellitus
(DM), malnutrition and physical inactivity, which are well-established risk factors for infection
and pneumonia [2]. Pneumonia is the most frequent post-stroke infection which constitute a
leading cause of early and long-term mortality and morbidity after stroke [3, 4]. Therefore,
identifying risk factors for pneumonia is important in prevention of the complication and
improving long-term outcome after stroke. In stroke patients, gastric acid suppressive medica-
tions of proton pump inhibitors (PPI) and H2 receptor antagonists (H2RA) are frequently pre-
scribed to control heart-burn symptom or prevent gastroduodenal injury. Growing evidence
suggests that the acid-suppressive medications may increase risk of pneumonia by attenuation
of the bactericidal effect of gastric acid [5, 6]. There were some prior researches for association
between pneumonia and exposure to the PPI and H2RA during acute period of stroke [7–9].
However, there is insufficient data for the relationship between the risk for post-stroke pneu-
monia and the medications during long-term follow-up period. Beside PPI and H2RA, there
are another types of anti-ulcer drugs called mucoprotective agents (rebamipide, teprenone,
irsogladine, ecabet, polaprezinc, sofalcone, sucralfate, and misoprostol) with no or less anti-
acid property [10]. Without gastric acid suppression, their effects on post-stroke pneumonia
might be different to PPI and H2RA. To evaluate effects of the anti-ulcer drugs on the risk for
post-stroke pneumonia, we conducted a retrospective cohort study using the nation-wide
health insurance database which contained long-term data for the development of pneumonia
and prescription records.
Materials and methods
Data sources
This was a retrospective cohort study using the nationwide population-based sample cohort by
the National Health Insurance Service in Korea (NHIS-NSC) [11]. NHIS-NSC was constructed
with 1,025,340 participants sampled randomly and stratified by sex, age, and household
income, who were approximately 2.2% of the total eligible Korean population in 2002. Because
NHIS is a single-payer program in Korea, NHIS-NSC contained whole health insurance claims
data including hospital visits, procedures, diagnosis, prescriptions and demographic informa-
tion of sex, age, household income, and death statistics of the included subjects. At each hospi-
tal visit diagnostic codes were recorded according to the International Statistical Classification
of Diseases, 10th revision (ICD-10). Requests for access to NHIS data can be made through the
homepage of National Health Insurance Sharing Service [http://nhiss.nhis.or.kr/bd/ab/
bdaba021eng.do]. To gain access to the data, a completed application form, a research proposal
and the applicant’s approval document from the institutional review board should be submit-
ted to and reviewed by the inquiry committee of research support in NHIS. The NHIS-NSC
data were fully anonymized and did not contain any identifiable information. This study was
approved, and informed consent was waived by the Institutional Review Board of Bundang
CHA Medical Center (2017-08-047).
Study subjects and outcome
We included patients aged� 20 years who hospitalized (admitted or visited emergent medical
center) with primary diagnosis of ischemic stroke (ICD–10 code of ‘I63’) between 2002 and
2013. To include only acute ischemic stroke patients, we selected patients who underwent
brain computed tomography or magnetic resonance imaging during hospitalization due to the
Post-stroke pneumonia with anti-ulcer drugs
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assumption that patients with acute stroke should undergo brain imaging [12]. Primary out-
come is time to development of pneumonia after discharge which is determined based on the
presence of diagnostic codes ‘J10–J18’[13–15]. To detect only patients who newly developed
pneumonia after stroke as outcome, we excluded patients who had diagnostic codes ‘J10–J18’
prior to admission or within a month after discharge of index stroke. Flowchart for inclusion
and exclusion criteria is shown in Fig 1. The included patients were followed up until the
development of pneumonia, loss of participant eligibility for NHIS, or December 2013.
Collection of prescription records
NHIS-NSC contained prescription data including drug name, dose, duration and date of pre-
scription. We collected prescription records of included patients for PPI (omeprazole,
Fig 1. Flowchart of included patients.
https://doi.org/10.1371/journal.pone.0216750.g001
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pantoprazole, lansoprazole, rabeprazole, esomeprazole, and dexlansoprazole), H2RA (ilapra-
zole, cimetidine, famotidine, lafutidine, nizatidine, ranitidine, and roxatidine), and mucopro-
tective agents (rebamipide, teprenone, irsogladine, ecabet, polaprezinc, sofalcone, sucralfate,
and misoprostol) which were available in Korea during study period. Based on the prescription
records, exposure to PPI, H2RA, and mucoprotective agents were accessed on every day of the
follow-up period, which were collected as time-dependent variables. According to the daily
dose of PPI and H2RA, they were classified into ‘low dose’ and ‘high dose’. ‘High dose’ is deter-
mined if daily dose is� 20 mg of omeprazole, 40mg of pantoprazole, 30mg of lansoprazole,
20mg rabeprazole, 30mg of esomeprazole, 30mg of dexlansoprazole, 20mg of ilaprazole,
800mg of cimetidine, 40mg of famotidine, 20mg of lafutidine, 300mg of nizatidine, 300mg of
ranitidine, and 150mg of roxatidine; the cut-off values are defined daily dose determined by the
World Health Organization [16].
Covariates
We collected data for baseline characteristics of sex, age, household income at index stroke
and the presence of underlying risk factors of hypertension, DM, myocardial infarction (MI),
atrial fibrillation (AF), and chronic obstructive pulmonary disease (COPD). In NHIS-NSC,
age was grouped into 5-year periods, which was treated as a continuous variable in the analysis.
We stratified the household income level into tertile groups (low, middle, and high). The his-
tory of hypertension (I10–15), DM (E08–11, E13–14), MI (I21), AF (I48), and COPD (J42, J43
[except for J43.0], J44) were determined by the presence of diagnostic code before or during
admission period of index stroke [12,17,18]. Hypertension and DM were recognized as rele-
vant only if the subjects received one or more prescriptions of antihypertensive or antidiabetic
medications with the diagnosis [19]. Use of thrombolysis (653500660, 653500670 for intra-
venous and M6631, M6632, M6633 for intra-arterial) was determined by the procedure codes.
We accessed length of hospital stay; patients were grouped into two groups (� 17 days, > 17
days) by the median length of hospital stay at index stroke. Hospitals at index stroke were clas-
sified into ‘general hospital’ and ‘hospital or clinic’ based on the healthcare resources (the for-
mer being a large-scale hospital). Years of index stroke were grouped according to the
following: [2002–2005], [2006–2009], and [2010–2013].
Statistical analyses
Use of PPI, H2RA, and mucoprotective agents though follow-up period were treated as time-
dependent variables for the statistical analyses. Plots for estimated pneumonia-free probability
according to the use of medications during follow-up are illustrated using the method estab-
lished by Simon and Makuch [20]. The hazard ratio (HR) and 95% confidence interval (CI)
were derived from time-dependent Cox proportional hazard regression models. The assump-
tion of proportional hazards of the Cox models was tested by evaluating scaled Schonfeld
residuals, which were found to be satisfactory. To identify independent risk factors for pneu-
monia, adjustments were performed for sex, age (as continuous variable), history of hyperten-
sion, DM, MI, AF, COPD, use of thrombolysis, household income, length of hospital stay,
hospital type and year of index stroke. The data manipulation and statistical analyses were per-
formed with PostgreSQL, version 10.1 (The PostgreSQL Global Development Group; https://
www.postgresql.org/), and R software, version 3.4.4 (The R Foundation for Statistical Comput-
ing, Vienna, Austria; http://www.R-project.org/). A two-sided p value of<0.05 was considered
to be statistically significant.
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Results
Study subjects
This study finally included 8,319 patients of acute ischemic stroke who discharged without
pneumonia (Fig 1). The median age group was 65–69 [interquartile rage, 55–59; 75–79] years
old, and males were 54.7% (Table 1). Fig 2 demonstrates the proportions of patients who
received PPI, H2RA, and mucoprotective agents throughout the follow-up period after stroke.
The proportion of patients received the medications were relatively consistent during follow-
up. At 1-year after stroke discharge, there were 6710 patients who remained at risk for pneu-
monia (they survived and had no pneumonia until the time point). Among the 6710 patients
at 1-year, the number of patients who received PPI, H2RA, mucoprotective agents at the time
were 147 (2.2%), 971 (14.5%), and 1131 (16.9%), respectively. Table 2 shows the difference in
characteristics of patients who received and those who did not receive the medications at
1-year.
Risk for pneumonia
During 3.95 ± 3.01 years (mean ± standard deviation) of follow-up, there were 2,035 (24.5%)
patients who developed pneumonia after discharge from index stroke. Fig 3 demonstrates the
estimated pneumonia-free probability curves considering the use of PPI, H2RA, and muco-
protective agents during follow-up as time-dependent variables. Among the anti-ulcer drugs,
treatment with PPI and H2RA was associated with an increased risk for pneumonia (Fig 3A
Table 1. Baseline characteristics of included patients.
Variable N (%) or median [interquartile range]
Total number of patients N = 8319
Sex, male 4551 (54.8)
Age, year 65–69 [55–59; 75–79]
Hypertension 6038 (72.6)
Diabetes mellitus 2408 (28.9)
Myocardial infarction 610 (7.3)
Atrial fibrillation 811 (9.7)
Chronic obstructive pulmonary disease 1705 (20.5)
Thrombolysis (intravenous or intraarterial) 187 (2.2)
Household income
low 2730 (32.8)
middle 2993 (36.0)
high 2596 (31.2)
Hospital type
general hospital 7017 (84.3)
hospital or clinic 1302 (15.7)
Length of hospital stay
�17 days 4491(51.6)
>17 days 4028 (48.4)
Year of index stroke
2002–2005 2392 (28.8)
2006–2009 3168 (38.1)
2010–2013 2759 (33.2)
Data are number (%) or median [interquartile range].
https://doi.org/10.1371/journal.pone.0216750.t001
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and Fig 3B), but treatment with mucoprotective agents was not (Fig 3C). In the multivariate
time-dependent Cox regression model (Table 3), there was a significantly increased risk for
pneumonia with use of PPI (adjusted HR [95% CI], 1.56 [1.24–1.96], p<0.001) and H2RA
(adjusted HR [95% CI], 1.40 [1.25–1.58], p<0.001). On the other hand, use of mucoprotective
agents was not associated with the development of pneumonia (adjusted HR [95% CI], 0.89
[0.78–1.01], p = 0.055). We further analyzed the risk for pneumonia according to the daily
dose of PPI, and H2RA (Table 4). There were significant dose-response relationships between
risk for pneumonia and daily dose of the anti-acid medications (more pneumonia risk with
high dose of PPI and H2RA).
Discussion
In this study, we evaluated the risk for pneumonia according to the use of PPI, H2RA, and
mucoprotective agents during the long-term follow-up period after acute ischemic stroke
using the nation-wide health insurance claims database in Korea. The development of pneu-
monia after acute ischemic stroke was common; 24.5% of included patients had pneumonia
during the mean follow-up period of 3.95 ± 3.01 years. Main finding of this study was that use
Fig 2. Proportion of patients who received medications thoughout the post-stroke period. Mucoprotective agents include rebamipide, teprenone,
irsogladine, ecabet, polaprezinc, sofalcone, sucralfate, and misoprostol. Abbreviations: H2RA, H2-receptor antagonist; PPI, proton-pump inhibitor.
https://doi.org/10.1371/journal.pone.0216750.g002
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of the anti-acid medications of PPI and H2RA was significantly associated with the develop-
ment of post-stroke pneumonia. In contrast to the anti-acid medications, use of mucoprotec-
tive agents was not associated with the risk of pneumonia.
For stroke patients, PPI and H2RA are widely subscribed to the control of gastric symptom,
prevention and treatment for peptic ulcer and gastrointestinal injury. Ischemic stroke patients
generally need life-long use of antiplatelet or anticoagulation for secondary prevention of car-
diovascular events. Aspirin is most frequently prescribed antiplatelet, which cause gastric
mucosal injury [21]. Concomitant use of non-steroidal anti-inflammatory drugs (NSAID) is
also common in patients with cardiovascular risk factors [22]. It is well known that aspirin and
NSAID can induce acute and chronic gastroenteropathy; NSAID-induced gastroenteropathy.
Aspirin and NSAID inhibit prostaglandin-endoperoxide synthase which reduces the basal pro-
tection of cytoprotective prostaglandin E2 and prostaglandin I2 in the gastric mucosa [23].
Reduced prostaglandins can mediate gastrointestinal injury by low mucosal blood flow,
decreased secretion of bicarbonate and mucous, impaired proliferation and repair, and
increase of gastric acid and inflammatory molecules such as leukotriene [24]. Prostaglandin
Table 2. Clinical characteristics of patients according to current use of medications at 1-year after index stroke.
Medication Proton pump inhibitor H2-receptor antagonist mucoprotective agent�
Variable No use
(N = 6563)
Use (N = 147) P
value
No use
(N = 5739)
Use (N = 971) P
value
No use
(N = 5579)
Use (N = 1131) P
value
Sex, male 3580 (54.5) 85 (57.8) .481 3183 (55.5) 482 (49.6) .001 3037 (54.4) 628 (55.5) .523
Age, year 65–69 [55–59;
70–74]
65–69 [55–59;
75–79]
65–69 [55–59;
70–74]
65–69 [55–59;
75–79]
65–69 [55–59;
70–74]
65–69 [55–59;
70–74]
Hypertension 4661 (71.0) 116 (78.9) .046 4020 (70.0) 757 (78.0) <
.001
3930 (70.4) 847 (74.9) .003
Diabetes mellitus 1789 (27.3) 46 (31.3) .321 1538 (26.8) 297 (30.6) .016 1487 (26.7) 348 (30.8) .005
Myocardial infarction 459 (7.0) 10 (6.8) <
.001
403 (7.0) 66 (6.8) 0.852 383 (6.9) 86 (7.6) .410
Atrial fibrillation 567 (8.6) 16 (10.9) .419 498 (8.7) 85 (8.8) .987 469 (8.4) 114 (10.1) .078
Chronic obstructive
pulmonary disease
1218 (18.6) 49 (33.3) <
.001
1046 (18.2) 221 (22.8) .001 1026 (18.4) 241 (21.3) .025
Thrombolysis (intravenous
or intraarterial)
122 (1.9) 2 (1.4) <
.001
92 (1.6) 32 (3.3) <
.001
90 (1.6) 34 (3.0) .002
Household income .983 .105 .724
low 2112 (32.2) 48 (32.7) 1821 (31.7) 339 (34.9) 1803 (32.3) 357 (31.6)
middle 2370 (36.1) 52 (35.4) 2076 (36.2) 346 (35.6) 2002 (35.9) 420 (37.1)
high 2081 (31.7) 47 (32.0) 1842 (32.1) 286 (29.5) 1774 (31.8) 354 (31.3)
Hospital type .506 .398 .001
general hospital 5561 (84.7) 128 (87.1) 4875 (84.9) 814 (83.8) 4693 (84.1) 996 (88.1)
hospital or clinic 1002 (15.3) 19 (12.9) 864 (15.1) 157 (16.2) 886 (15.9) 135 (11.9)
Length of hospital stay .803 .008 <
.001
�17 days 3436 (52.4) 79 (53.7) 3045 (53.1) 470 (48.4) 2996 (53.7) 519 (45.9)
>17 days 3127 (47.6) 68 (46.3) 2694 (46.9) 501 (51.6) 2583 (46.3) 612 (54.1)
Year of index stroke <
.001
<
.001
<
.001
2002–2005 2093 (31.9) 9 (6.1) 1862 (32.4) 240 (24.7) 1890 (33.9) 212 (18.7)
2006–2009 2707 (41.2) 54 (36.7) 2396 (41.7) 365 (37.6) 2278 (40.8) 483 (42.7)
2010–2013 1763 (26.9) 84 (57.1) 1481 (25.8) 366 (37.7) 1411 (25.3) 436 (38.5)
�rebamipide, teprenone, irsogladine, ecabet sodium, polaprezinc, sofalcone, sucralfate, and misoprostol.
https://doi.org/10.1371/journal.pone.0216750.t002
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independent mucosal injury is also present with topical effects by salicylate or chemical prod-
ucts of NSAID [25]. Clopidogrel, another commonly used antiplatelet, can cause a similar
degree of gastric mucosal damage with aspirin [26]. Gastrointestinal bleeding is a serious and
potentially life-threatening complication associated with use of antiplatelet and anticoagulation.
American Heart Association guidelines for coronary artery disease suggest that use of PPI is rea-
sonable for patients with dual antiplatelet treatment and at increased risk of gastrointestinal
bleeding, including those with advanced age and those with concomitant use of warfarin, ste-
roids, or NSAID [27]. For treatment or prevention of NSAID-induced gastroenteropathy, PPI
is the recommended treatment of choice [28].
Fig 3. Estimated pneumonia-free probability according to the use of medications during post-stroke follow-up period. Each plot illustrates estimated
pneumonia-free survival curves according to the use of PPI (A), H2RA (B), and mucoprotective agents (C) during the followed-up period after stroke.
Mucoprotective agents include rebamipide, teprenone, irsogladine, ecabet, polaprezinc, sofalcone, sucralfate, and misoprostol. Abbreviations: H2RA, H2-
receptor antagonist; PPI, proton-pump inhibitor.
https://doi.org/10.1371/journal.pone.0216750.g003
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Aside from gastric protection, there is a clinical concern for that PPI and H2RA may
increase the development of pneumonia. PPI and H2RA have gastroprotective effects by
reducing secretion of gastric acid and acidity in stomach. The acidity of gastric juice is one of
primary bactericidal barrier and the rate of killing is strongly dependent to the low pH [29,30].
Considering the biological rationale, bactericidal barrier of gastric acid and anti-acid property
of PPI and H2RA, use of the acid suppressants may expose to the risk for pneumonia, espe-
cially stroke patients with swallowing difficulty who are highly susceptible to respiratory infec-
tions. There were prior studies which reported that risk for pneumonia was increased with the
exposure to PPI or H2RA following acute stroke [7–9]. One hospital-based cohort study with
1676 patients admitted for acute stroke reported that exposure to PPI (adjusted odds ratio
(OR) [95% CI], 2.7 [1.4–5.4]) and H2RA (adjusted OR [95% CI], 1.6 [0.8–3.4]) during admis-
sion were associated with significantly increased risk for hospital-acquired pneumonia [7]. In
research with Taiwanese National Health Insurance Research Database, risk of post-stroke
pneumonia increased with exposure to H2RA, PPI, or both (adjusted HR; 1.40, 1.38, and 1.57,
respectively) [31]. In a hospital based retrospective study including 355 acute stroke patients
Table 3. Effects of medications on the risk for post-stroke pneumonia.
Variable adjusted HR [95% CI] P value
Time-independent variables
Sex, male 1.19 [1.09–1.31] < .001
Age, per 5-year 1.21 [1.18–1.24] < .001
Hypertension 1.05 [0.94–1.16] .393
Diabetes mellitus 1.25 [1.13–1.37] < .001
Myocardial infarction 1.10 [0.93–1.29] .254
Atrial fibrillation 1.19 [1.02–1.38] .025
Chronic obstructive pulmonary disease 1.28 [1.15–1.43] < .001
Thrombolysis (intravenous or intraarterial) 1.03 [0.69–1.54] .885
Household income
low Ref –
middle 0.96 [0.86–1.07] .439
high 0.97 [0.87–1.08] .576
Hospital type
general hospital Ref –
hospital or clinic 1.24 [1.10–1.39] < .001
Length of hospital stay
�17 days Ref –
>17 days 1.00 [0.91–1.09] .986
Year of index stroke
2002–2005 Ref –
2006–2009 0.93 [0.84–1.03] .148
2010–2013 0.93 [0.81–1.07] .337
Time-dependent variables
Proton pump inhibitor 1.56 [1.24–1.96] < .001
H2-receptor antagonist 1.40 [1.25–1.58] < .001
Mucoprotective agents� 0.89 [0.78–1.01] .062
Data were obtained from multivariate time-dependent Cox proportional hazard regression model. Adjustments were
made to the variables listed in this table.
�rebamipide, teprenone, irsogladine, ecabet sodium, polaprezinc, sofalcone, sucralfate, and misoprostol.
Abbreviations: HR, hazard ratio; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0216750.t003
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who could not feed orally for 14 days, the relative risk of H2RA and PPI on pneumonia were
1.24 (95% CI; 0.85–1.81) and 2.00 (95% CI; 1.12–3.57) compared to no usage, respectively [9].
An observational study using the national Japanese Diagnosis Procedure Combination inpa-
tient database showed similar incidence of pneumonia between users of PPI and H2RA after
acute stroke [32]. In patients with intracerebral hemorrhage, nosocomial pneumonia was
more common in those who received PPI than those did not [8]. In the line with the prior
reports of positive relationship between use of acid-suppressive medications and post-stroke
pneumonia, we added evidence that use of PPI and H2RA throughout long-term follow-up
period were significantly associated with increased risk for post-stroke pneumonia. Our find-
ing of increased risk in proportion to the dose of PPI and H2RA supported the deteriorating
effect of the anti-acid medications on the risk for pneumonia. Considering the potential risk
for pneumonia, clinician should use caution in prescribing anti-acid medications over the
long-term without definite indications. The American Heart Association guidelines for coro-
nary artery disease against the routine use of PPI for patients at low risk of gastrointestinal
bleeding without clear indication for the PPI therapy [27].
In this study, there was no increased risk for pneumonia with mucoprotective agents which
were also frequently prescribed for control of gastrointestinal symptom or prevention of ulcer.
Mucoprotective agents have been used for protection of gastroduodenal mucosa, healing of
ulcers, and treatment of gastritis. Without suppression of gastric acid, mucoprotective agents
have multiple gastroprotective mechanisms through increase gastric blood flow, prostaglandin
biosynthesis and decrease free oxygen radicals [33]. To minimalize the potential risk for post-
stroke pneumonia with the anti-acid medications, mucoprotective agents might be safe alter-
native for gastrointestinal symptom control or mucosal protection to the stroke patients
who are susceptible for pneumonia. Compared to anti-acid medications, safety of the muco-
protective agents on pneumonia has been suggested [34]. A meta-analysis and trial sequential
analysis of randomized trials showed that sucralfate reduced intensive care unit-acquired
pneumonia compared to H2RA in critically ill patients [35]. Sucralfate is one of mucoprotec-
tive agents which form a coating over ulcers and provide physical barrier to gastrointestinal
tract (mucosal cytoprotectant). Misoprostol is a synthetic prostaglandin E1 analogue approved
by the Food and Drug Administration for the prevention of drug for prevention of NSAID-
associated ulcers. Misoprostol have mucosal protective property by enhancing gastric mucosal
blood flow and secretion of mucus and bicarbonate [36]. Multiple clinical trials have demon-
strated misoprostol is as effective as PPI for prevention and treatment of gastrointestinal ulcers
[37]. Rebamipide is a novel gastroprotective drug which has mechanism of stimulating prosta-
glandin generation in gastric mucosa, inhibiting neutrophil activation and inflammatory cyto-
kines, and helps in replacement of lost tissue by increasing the expression of epidermal growth
Table 4. Effect of anti-acid medications on pneumonia risk according to the dose intensity.
Medication Dose intensity adjusted HR [95% CI] P value P value for trend
Proton pump inhibitor no use Ref – < .001
low dose 1.34 [0.97–1.85] .079
high dose 1.85 [1.36–2.51] < .001
H2-receptor antagonist no use Ref – < .001
low dose 1.38 [1.20–1.60] < .001
high dose 1.43 [1.19–1.70] < .001
Data are derived by multivariate time-dependent Cox proportional hazard regression model adjusted for variables listed in Table 3.
Abbreviations: HR, hazard ratio; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0216750.t004
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factor (EGF) and EGF receptors [38–40]. Rebamipide has anti-oxidative and anti-inflamma-
tory properties which scavenges oxygen-derived free radicals and inhibits the production
[41,42]. Randomized trial demonstrated that rebamipide prevented NSAID-induced ulcer as
effectively as misoprostol [43]. Rebamipide was equivalent to treatment with lansoprazole in
the healing of endoscopic submucosal dissection-induced ulcers [44].
As main strength of our study, use of nation-wide health insurance claims database makes
it possible to include> 8000 patients with acute ischemic stroke. Based on the database, we
could undergo longitudinal follow-up of the included patients for the development of pneu-
monia and prescription records. With the strengths, we should acknowledge potential limita-
tions of this study. The risk of developing pneumonia after stroke could be positively related
with stroke severity and post stroke disability [45]. Unfortunately, health insurance claims
database in Korea did not include data of stroke severity or disability such as National Insti-
tutes of Health Stroke Scale or modified Rankin scale. Thus, we could not collect the clinical
data of stroke severity or functional disability after stroke, which might be significant prognos-
tic factor for pneumonia. As an alternative, we collected the data for length of hospital stay at
index stroke known to be correlated with stroke severity and disability [46, 47]. In the multi-
variate model adjusted for the length of hospital stay, the association of treatment with PPI
and H2RA with increased risk for post-stroke pneumonia remained significant. In addition,
we could not collect data of smoking, which might be another important associative factor for
pneumonia, because of lack of the data in health insurance database. Due to the nature of ret-
rospective observational design, we could not conclude the causal relationship between the use
of medications and risk for pneumonia. There might be uncollected difference in characteris-
tics of patients who received medications and those did not. Because, use of medications were
determined based on prescription records, there may be gap between prescription data and
individual patient’s actual intake. We defined the development of pneumonia based on to the
presence of diagnostic code in NHIS-NSC. Although identification of pneumonia based on
ICD-10 code is known to be a reliable, there might be miss-classification of patients who did
not visit hospital or by error of registration in clinical practice [13]. Although our study was
performed with nationwide cohort, it is difficult to assure that the sample size was adequate to
verify the association of pneumonia with anti-ulcer drugs. Further studies are needed to estab-
lish the effect of different classes of anti-ulcer drugs on post-stroke pneumonia.
Conclusions
Treatment with PPI and H2RA is associated with increased risk for post-stroke pneumonia,
but treatment with mucoprotective agents is not. Clinician should be aware of the potential
impact of anti-acid medications on pneumonia, frequent complication of stroke patients.
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